FDA to Cy­to­Dyn: Those 2 Covid tri­als you keep tout­ing both failed on all end­points and your sub­group analy­sis does­n't help. Are we clear now?

As a mat­ter of of­fi­cial pol­i­cy, the FDA doesn’t com­ment about un­ap­proved drugs and the da­ta gath­ered to back them.

As an un­of­fi­cial pol­i­cy, though, the agency can still be pro­voked by a seem­ing­ly un­end­ing stream of pro­mo­tion­al re­leas­es to call a com­pa­ny out for a com­plete and ut­ter fail­ure.

So it was to­day with Cy­to­Dyn, a biotech com­pa­ny that has a habit of blast­ing state­ments out about their drug leron­limab, which has been tout­ed as a po­ten­tial treat­ment for Covid-19.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE